Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

Stopped early · Phase 1

Conditions studied: Preleukemia, Myeloproliferative Disorders, Lymphoma, Myeloma, Graft Versus Host Disease

In brief

This is a clinical research study designed to evaluate whether the administration of a vaccine to patients after transplant consisting of a minor histocompatibility antigen (mHag peptide) mixed with G-CSF (a drug intended to stimulate the immune system) can stimulate increased graft versus leukemia (GVL) responses without causing graft-versus-host disease (GVHD).

Key facts

Study ID

NCT00943293

Run by

University of Chicago

People needed

1

Starts

2003-05-01

Expected to finish

2012-01-01

Last updated by the study team

2014-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed or refractory acute myelogenous or lymphoid leukemia.
• Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.
• Chronic myelogenous leukemia in accelerated phase or blast-crisis.
• Chronic myelogenous leukemia in second or subsequent chronic phase
• Recurrent or refractory malignant lymphoma or Hodgkin's disease
• Multiple myeloma at high risk for disease recurrence.
• Chronic lymphocytic leukemia, relapsed or with poor prognostic features.
• Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.

You may not qualify if…

• Clinical progression.
• Contra-indications for vaccination.

Where it is running

• The Uniiversity of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.